Communiqués Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L2097

Recherche biotechnologique et médicale

Temps Différé OTC Markets 16:15:12 02/09/2026			Varia. 5j.	Varia. 1 janv.
0,000500 ^USD	0,00%		-98,47%	-99,72%

31/03	Lipella Pharmaceuticals Inc. se place sous la protection du Chapitre 11	RE
30/03	Lipella Pharmaceuticals Inc. se place sous la protection du Chapitre 11	CI

Communiqués

18/09/25	Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus	AQ
15/09/25	Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus	PR
25/06/25	Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting	AQ
20/06/25	Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market	AQ
17/06/25	Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology	AQ
04/06/25	Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development	AQ
15/05/25	Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting	AQ
23/04/25	Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”	AQ
22/04/25	Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025	AQ
08/04/25	Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus	AQ
31/03/25	Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast	AQ
07/03/25	Spartan Capital Securities, LLC Announces Key February Transactions	AQ
04/03/25	Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement	AQ
11/02/25	Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus	AQ
06/02/25	Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus	AQ
10/01/25	Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement	AQ
03/12/24	Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus	AQ
21/11/24	Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group	AQ
12/11/24	Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform	AQ
01/11/24	Lipella Pharmaceuticals : Announces 1 for 8 Reverse Stock Split Form 8 K	PU
01/11/24	Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split	AQ
29/10/24	Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference	AQ
15/10/24	Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform	AQ
09/10/24	Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit	AQ
25/09/24	PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month	AQ